Literature DB >> 6375339

Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide.

I K Inouye, B M Massie, N Benowitz, P Simpson, D Loge.   

Abstract

Fourteen hypertensive patients with a mean sitting systolic and diastolic blood pressure (BP) of 153 +/- 16/100 +/- 4 mm Hg were treated successively with hydrochlorothiazide and diltiazem for 8 weeks each. The BP response and changes in heart rate, left ventricular size and function, and plasma catecholamine concentrations and renin activity were monitored. The 2 drugs had comparable antihypertensive effects, with mean decreases of 14, 9 and 11 mm Hg for the sitting, standing and supine diastolic BP, respectively, during hydrochlorothiazide treatment and mean decreases of 16, 18 and 12 mm Hg during diltiazem treatment. Heart rate was unchanged, although plasma norepinephrine concentrations increased significantly during diltiazem treatment. Plasma renin activity increased slightly, from 0.6 to 0.9 ng/ml/hour during diltiazem treatment, but the change was not significant (p less than 0.10). Left ventricular ejection fraction and end-diastolic volume were not affected by either agent. In conclusion, diltiazem is an effective antihypertensive agent, which because of its benign side effect profile, may be useful as a step 1 agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375339     DOI: 10.1016/0002-9149(84)90584-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Antihypertensive monotherapy with tablet (prompt-release) diltiazem: multicenter controlled trials.

Authors:  P E Pool; J M Nappi; M A Weber
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Calcium channel blocking agents and the heart.

Authors:  J Kenny
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

4.  A multicenter comparison of isradipine and prazosin for treatment of essential hypertension.

Authors:  S L Swartz; L M Gonasun; R G McAllister; U Thadani
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 5.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

Review 6.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 7.  Calcium antagonists and exercise performance.

Authors:  W Kindermann
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

8.  Effect of felodipine on the serum lipid profile of patients with hypertension.

Authors:  M Kaur; K Kaur; G K Bedi; G S Sidhu; R Sikand
Journal:  Indian J Clin Biochem       Date:  2000-07

9.  Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers.

Authors:  G Bianchetti; C Dubruc; V Sultana; G Houin; P Rosenzweig
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.